LUNDBECK-FOUNDATION
5.3.2024 16:31:25 CET | Business Wire | Press release
The Lundbeck Foundation has announced the recipients of The Brain Prize 2024, the world’s largest award for outstanding contributions to neuroscience. This year’s award recognizes the pioneering work of three leading neuroscientists – Professor Larry Abbott at Columbia University (USA), Professor Terrence Sejnowski at the Salk Institute (USA), and Professor Haim Sompolinsky at Harvard University (USA) and the Hebrew University (Israel).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240305504553/en/
Credit: The Lundbeck Foundation
Theoretical and computational neuroscience permeates neuroscience today and is of increasingly growing importance. The winners of The Brain Prize 2024 have made pioneering contributions to these scientific areas by uncovering some of the principles that govern the brain’s structure, function, and the emergence of cognition and behaviour.
The Brain Prize 2024 worth DKK 10 million (€1.3 million) is awarded to:
Larry Abbott (USA), Terrence Sejnowski (USA), and Haim Sompolinsky (Israel/USA) for their Foundational work in Computational and Theoretical Neuroscience.
Chair of The Brain Prize Selection Committee, Professor Richard Morris, explains the reasoning behind this year’s award:
“It is inconceivable to imagine modern brain sciences without the concomitant development of computational and theoretical neuroscience. The three scientists have applied novel and sophisticated approaches from physics, mathematics, and statistics to study the brain. They have developed vital tools for the analysis of highly complex datasets acquired by modern day experimental neuroscientists.
The three prize winners have also proposed conceptual frameworks for understanding some of the brain’s most fundamental processes such as learning, memory, perception and how the brain generates maps of the external world. They have also provided crucial new insights into what may go awry in several devastating disorders of the nervous system, such as epilepsy, Alzheimer’s disease, and schizophrenia. In addition, their scientific achievements have paved the way for the development of brain-inspired artificial intelligence, one of the emerging and transformational technologies of our time.”
On behalf of the Lundbeck Foundation, CEO Lene Skole extends her warmest congratulations to each of the three Brain Prize recipients:
“Their pioneering research has created trailblazing knowledge and paved the way for other scientists to better understand critical brain functions, also in relation to diseases. It aligns fully with our purpose of bringing discoveries to lives. Each of their scientific endeavours began in the 70’s, and their determination, courage and persistence over decades should serve as inspiration for other scientists, and indeed be rewarded.”
FACTS
The human brain consists of approximately 100 billion neurons connected by trillions of synaptic connections. Every function the brain performs relies on the flow of information through these staggeringly complex networks of neurons. A fundamental goal of neuroscience is to understand how these networks are wired together, and how the patterns of neural activity within them give rise to cognition and behaviour. The sheer complexity of the brain means that understanding its language requires theoretical and computational approaches.
Theoretical and computational neuroscience uses mathematics, computer science, theoretical analysis, and abstractions of the brain to understand the principles that govern its structure, how it processes information, generates behaviour, and gives rise to cognitive abilities as perception, imagination, intelligence, the formation of knowledge, memory, problem-solving, decision-making, and the production of language. The field has laid the foundations for the development of AI - one of the most revolutionary developments in modern science.
MORE INFO
Find out more – see the information pack of The Brain Prize 2024 >>
About The Brain Prize
The Brain Prize is the world’s largest neuroscience research prize, and it is awarded each year by the Lundbeck Foundation. The Brain Prize recognises highly original and influential advances in any area of brain research, from basic neuroscience to applied clinical research. Recipients of The Brain Prize may be of any nationality and work in any country in the world. Since it was first awarded in 2011, The Brain Prize has been awarded to 47 scientists from 10 ten different countries. The Brain Prize recipients are presented with their award by His Royal Highness, King Frederik of Denmark, at a ceremony in the Danish capital, Copenhagen.
About the Lundbeck Foundation
The Lundbeck Foundation is an enterprise foundation encompassing a comprehensive range of commercial and philanthropic activities – all united by its strong purpose; Bringing Discoveries to Lives. The Foundation is the long-term and engaged owner of several international healthcare and medtech companies – Lundbeck, Falck, ALK, Ellab, and Ferrosan Medical Devices – and an active investor in business, science and people through its commercial investments in the financial markets; in biotech companies based on Danish research and through philanthropic grants to science talents and programmes in Danish universities. The Foundation’s philanthropic grants amount to more than DKK 500m annually primarily focusing on the brain – including the world’s largest personal prize awarded in neuroscience, The Brain Prize.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240305504553/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Fortegra Completes Acquisition by DB Insurance29.5.2026 22:30:00 CEST | Press release
The Fortegra Group, Inc. ("Fortegra"), a global specialty insurance company, today announced the completion of its acquisition by DB Insurance Co., Ltd. ("DB"), one of Korea's leading property and casualty insurers. The transaction, announced on September 26, 2025, received all required regulatory and stockholder approvals. Fortegra will operate independently, maintaining its existing leadership team, distribution relationships, and underwriting discipline. Agents, distribution partners, and customers will continue to experience the service excellence that has defined the Fortegra experience. Richard Kahlbaugh, Chairman and CEO of Fortegra, said: "Every company eventually changes ownership. That is the nature of business. The closing of this acquisition is a starting point. As part of DB Insurance, Fortegra is positioned to expand our business geographically, enhance our capabilities and deepen our market presence in the US, Europe, the United Kingdom and Asia. Together, DB Insurance a
SINOVAC Receives Nasdaq Notification Regarding Late Filing of 2025 Annual Report29.5.2026 22:01:00 CEST | Press release
Sinovac Biotech Ltd. (Nasdaq: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it received a notification letter dated May 20, 2026 (the “Notification Letter”), from Nasdaq Listing Qualifications (“Nasdaq”) stating that as of May 8, 2026, the Company had regained compliance with the periodic filing and interim financial requirements in Nasdaq Listing Rules 5250(c)(1) (the “Periodic Filing Rule”) and 5250(c)(2), as required by the Panel’s decision dated January 21, 2026. As previously disclosed on January 22, 2026, under the Panel’s decision, SINOVAC was required to, on or before May 11, 2026, demonstrate compliance with such Nasdaq Listing Rules by completing filings of its annual report for the year ended December 31, 2024, on Form 20-F and an interim balance sheet and income statement as of the end of its second quarter of 2025 on Form 6-K. The Company timely completed such filings as required by the Panel’s decision.
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
